A detailed history of Royal Bank Of Canada transactions in Kal Vista Pharmaceuticals, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 3,993 shares of KALV stock, worth $35,737. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,993
Previous 3,582 11.47%
Holding current value
$35,737
Previous $42,000 9.52%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$9.46 - $15.39 $3,888 - $6,325
411 Added 11.47%
3,993 $46,000
Q2 2024

Aug 14, 2024

BUY
$10.35 - $12.49 $29,808 - $35,971
2,880 Added 410.26%
3,582 $42,000
Q1 2024

Nov 05, 2024

SELL
$11.07 - $16.04 $31,881 - $46,195
-2,880 Reduced 80.4%
702 $8,000
Q1 2024

May 15, 2024

SELL
$11.07 - $16.04 $100,604 - $145,771
-9,088 Reduced 92.83%
702 $8,000
Q4 2023

Feb 14, 2024

BUY
$7.58 - $12.25 $42,175 - $68,159
5,564 Added 131.66%
9,790 $119,000
Q3 2023

Nov 14, 2023

SELL
$8.95 - $11.35 $2,380 - $3,019
-266 Reduced 5.92%
4,226 $40,000
Q2 2023

Aug 14, 2023

BUY
$7.73 - $10.57 $24,063 - $32,904
3,113 Added 225.74%
4,492 $40,000
Q1 2023

May 15, 2023

SELL
$6.3 - $8.39 $18,603 - $24,775
-2,953 Reduced 68.17%
1,379 $10,000
Q4 2022

Feb 14, 2023

SELL
$4.2 - $14.24 $23,163 - $78,533
-5,515 Reduced 56.01%
4,332 $29,000
Q3 2022

Nov 14, 2022

BUY
$9.85 - $16.83 $95,633 - $163,402
9,709 Added 7035.51%
9,847 $143,000
Q2 2022

Aug 15, 2022

SELL
$8.16 - $15.1 $10,102 - $18,693
-1,238 Reduced 89.97%
138 $1,000
Q1 2022

May 16, 2022

SELL
$11.2 - $16.97 $40,264 - $61,007
-3,595 Reduced 72.32%
1,376 $20,000
Q4 2021

Feb 14, 2022

BUY
$12.36 - $18.28 $32,704 - $48,368
2,646 Added 113.81%
4,971 $66,000
Q3 2021

Nov 15, 2021

SELL
$17.11 - $24.49 $9,838 - $14,081
-575 Reduced 19.83%
2,325 $41,000
Q2 2021

Aug 16, 2021

BUY
$23.12 - $29.91 $67,048 - $86,739
2,900 New
2,900 $70,000

Others Institutions Holding KALV

About KalVista Pharmaceuticals, Inc.


  • Ticker KALV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 24,602,000
  • Market Cap $220M
  • Description
  • KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral p...
More about KALV
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.